TCGA-66-2800-01A-01R-1201-07
— · cohortSQ2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ2
- subtype
- cohortSQ2
- age_years
- 70
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MTORC1_SIGNALING+0.430
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.430
- MYC_TARGETS_V1+0.410
- OXIDATIVE_PHOSPHORYLATION+0.410
- DNA_REPAIR+0.400
- E2F_TARGETS+0.390
- UV_RESPONSE_UP+0.370
- HYPOXIA+0.360
- MYC_TARGETS_V2+0.360
- ADIPOGENESIS+0.310
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.580
- INTERFERON_GAMMA_RESPONSE-0.410
- MITOTIC_SPINDLE-0.260
- PANCREAS_BETA_CELLS-0.220
- TGF_BETA_SIGNALING-0.170
- APICAL_JUNCTION-0.160
- UV_RESPONSE_DN-0.160
- MYOGENESIS-0.140
- ALLOGRAFT_REJECTION-0.130
- APICAL_SURFACE-0.110
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-21-1077-01A-01R-0692-07 | — | cohortSQ2 | 0.838 |
| 2 | SRR975592 | — | — | 0.780 |
| 3 | TCGA-73-4670-01A-01R-1206-07 | — | cohortA4 | 0.780 |
| 4 | TCGA-18-3411-01A-01R-0980-07 | — | cohortSQ2 | 0.778 |
| 5 | MNG709 | — | — | 0.768 |
| 6 | TCGA-18-4086-01A-01R-1100-07 | — | cohortSQ2 | 0.766 |
| 7 | 56218_S133 | — | cohortSQ1 | 0.761 |
| 8 | TCGA-22-5473-01A-01R-1635-07 | — | cohortSQ2 | 0.760 |
| 9 | SRR11296846 | — | — | 0.754 |
| 10 | SRR23303771 | — | — | 0.750 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MTORC1_SIGNALING | 0.430 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.430 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.410 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.410 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.400 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.390 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.370 | Idelalisib | — uncovered |
| HYPOXIA | 0.360 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.360 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.310 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.270 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.250 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.250 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.220 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.200 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.160 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.160 | Temsirolimus | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.160 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.150 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.150 | Idelalisib | — uncovered |